One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Novartis ADR just hit that mark, with a jump from 80 to 84 Monday.
This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the best stocks tend to have an 80 or better RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Novartis ADR is not currently near a potential buy zone. See if the stock goes on to form a sound pattern that could kick off a new price move.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 29%, compared to 18% in the prior report. Revenue increased from 9% to 15%. Keep an eye out for the company's next round of numbers on or around Apr. 29.
The company earns the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health and Protagonist Therapeutics are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
